Bayer HealthCare Completes Acquisition of Visible Genetics
As a result of the acquisition, Bayer HealthCare Diagnostics will gain VGI's FDA-approved automated OpenGene DNA sequencing systems and TRUGENE branded kits for the analysis of genes linked to disease. The products enhance Bayer's infectious disease portfolio and support its strategy to become a leader in the molecular diagnostics market.
"VGI's TRUGENE HIV-1 Genotyping Assay for HIV drug resistance testing and Bayer's recently approved VERSANT HIV-1 RNA 3.0 Assay (bDNA) for viral load testing are a powerful combination in the fight against HIV infection," Knueppel said.
The merging of the VERSANT family of assays and TRUGENE sequencing technologies will also allow Bayer to offer its customers access to assays that are critical in the diagnosis and management of hepatitis B and C infections. In addition, the VGI platform will be important for future applications in the management of diseases such as cancer, and inherited genetic disorders.
Topics
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.